FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040299750> ?p ?o ?g. }

• W2040299750 endingPage "57" @default.
• W2040299750 startingPage "52" @default.
• W2040299750 abstract "The Reduction in End Points in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study and the Irbesartan Diabetic Nephropathy Trial (IDNT) are two recently reported trials with hard end points, conducted in patients in advanced stages of diabetic nephropathy. Two other studies—the Irbesartan Microalbuminuria Study (IRMA)-2 and the Microalbuminuria Reduction with Valsartan study (MARVAL)—were trials conducted in patients with type 2 diabetes with microalbuminuria, a cardiovascular risk factor associated with early-stage diabetic nephropathy. These trials all had a common theme—that is, does an angiotensin receptor blocker (ARB) interfere with the natural history of diabetic nephropathy in a blood pressure-independent fashion? Without question, the results of these trials legitimatize the use of the ARB class in forestalling the deterioration in renal function, which is almost inevitable in the patient with untreated diabetic nephropathy. These data can now be added to the vast array of evidence supporting angiotensin-converting enzyme (ACE) inhibitor use in patients with nephropathy associated with type 1 diabetes. It now appears a safe conclusion that the patient with diabetic nephropathy should receive therapy with an agent that interrupts the renin-angiotensin system. These studies have not resolved the question as to whether an ACE inhibitor or an ARB is the preferred agent in people with nephropathy from type 1 diabetes, though the optimal doses of these drugs remain to be determined. Head-to-head studies comparing ACE inhibitors to ARBs in diabetic nephropathy are not likely to occur, so it is unlikely that comparable information will be forthcoming with ACE inhibitors. An evidence-based therapeutic approach derived from these trials would argue for ARBs to be the foundation of therapy in the patient with type 2 diabetes and nephropathy." @default.
• W2040299750 created "2016-06-24" @default.
• W2040299750 creator A5012514694 @default.
• W2040299750 creator A5020235273 @default.
• W2040299750 date "2002-01-01" @default.
• W2040299750 modified "2023-10-03" @default.
• W2040299750 title "Type 2 Diabetes: RENAAL and IDNT-The Emergence of New Treatment Options" @default.
• W2040299750 cites W150935824 @default.
• W2040299750 cites W1894131949 @default.
• W2040299750 cites W1979072447 @default.
• W2040299750 cites W1979741702 @default.
• W2040299750 cites W1982294754 @default.
• W2040299750 cites W2005928502 @default.
• W2040299750 cites W2022003821 @default.
• W2040299750 cites W2022846000 @default.
• W2040299750 cites W2024013841 @default.
• W2040299750 cites W2044773944 @default.
• W2040299750 cites W2046529630 @default.
• W2040299750 cites W2049397775 @default.
• W2040299750 cites W2056976690 @default.
• W2040299750 cites W2060993823 @default.
• W2040299750 cites W2061173243 @default.
• W2040299750 cites W2066640357 @default.
• W2040299750 cites W2067017612 @default.
• W2040299750 cites W2083008696 @default.
• W2040299750 cites W2084343172 @default.
• W2040299750 cites W2090895117 @default.
• W2040299750 cites W2116082851 @default.
• W2040299750 cites W2137530886 @default.
• W2040299750 cites W2147804563 @default.
• W2040299750 cites W2153539771 @default.
• W2040299750 cites W2156663584 @default.
• W2040299750 cites W2159729565 @default.
• W2040299750 cites W2317521667 @default.
• W2040299750 cites W3021250193 @default.
• W2040299750 cites W4213033871 @default.
• W2040299750 doi "https://doi.org/10.1111/j.1524-6175.2002.00749.x" @default.
• W2040299750 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11821641" @default.
• W2040299750 hasPublicationYear "2002" @default.
• W2040299750 type Work @default.
• W2040299750 sameAs 2040299750 @default.
• W2040299750 citedByCount "40" @default.
• W2040299750 countsByYear W20402997502012 @default.
• W2040299750 countsByYear W20402997502016 @default.
• W2040299750 countsByYear W20402997502017 @default.
• W2040299750 countsByYear W20402997502018 @default.
• W2040299750 countsByYear W20402997502021 @default.
• W2040299750 countsByYear W20402997502023 @default.
• W2040299750 crossrefType "journal-article" @default.
• W2040299750 hasAuthorship W2040299750A5012514694 @default.
• W2040299750 hasAuthorship W2040299750A5020235273 @default.
• W2040299750 hasBestOaLocation W20402997501 @default.
• W2040299750 hasConcept C126322002 @default.
• W2040299750 hasConcept C126894567 @default.
• W2040299750 hasConcept C134018914 @default.
• W2040299750 hasConcept C27016395 @default.
• W2040299750 hasConcept C2777180221 @default.
• W2040299750 hasConcept C2777387769 @default.
• W2040299750 hasConcept C2779611605 @default.
• W2040299750 hasConcept C2779922275 @default.
• W2040299750 hasConcept C2780259554 @default.
• W2040299750 hasConcept C2780288358 @default.
• W2040299750 hasConcept C2781184683 @default.
• W2040299750 hasConcept C2781203188 @default.
• W2040299750 hasConcept C2908929049 @default.
• W2040299750 hasConcept C555293320 @default.
• W2040299750 hasConcept C71924100 @default.
• W2040299750 hasConcept C84393581 @default.
• W2040299750 hasConceptScore W2040299750C126322002 @default.
• W2040299750 hasConceptScore W2040299750C126894567 @default.
• W2040299750 hasConceptScore W2040299750C134018914 @default.
• W2040299750 hasConceptScore W2040299750C27016395 @default.
• W2040299750 hasConceptScore W2040299750C2777180221 @default.
• W2040299750 hasConceptScore W2040299750C2777387769 @default.
• W2040299750 hasConceptScore W2040299750C2779611605 @default.
• W2040299750 hasConceptScore W2040299750C2779922275 @default.
• W2040299750 hasConceptScore W2040299750C2780259554 @default.
• W2040299750 hasConceptScore W2040299750C2780288358 @default.
• W2040299750 hasConceptScore W2040299750C2781184683 @default.
• W2040299750 hasConceptScore W2040299750C2781203188 @default.
• W2040299750 hasConceptScore W2040299750C2908929049 @default.
• W2040299750 hasConceptScore W2040299750C555293320 @default.
• W2040299750 hasConceptScore W2040299750C71924100 @default.
• W2040299750 hasConceptScore W2040299750C84393581 @default.
• W2040299750 hasIssue "1" @default.
• W2040299750 hasLocation W20402997501 @default.
• W2040299750 hasLocation W20402997502 @default.
• W2040299750 hasLocation W20402997503 @default.
• W2040299750 hasOpenAccess W2040299750 @default.
• W2040299750 hasPrimaryLocation W20402997501 @default.
• W2040299750 hasRelatedWork W2014498222 @default.
• W2040299750 hasRelatedWork W2027470168 @default.
• W2040299750 hasRelatedWork W2040299750 @default.
• W2040299750 hasRelatedWork W2040551893 @default.
• W2040299750 hasRelatedWork W2124902232 @default.
• W2040299750 hasRelatedWork W2130229820 @default.
• W2040299750 hasRelatedWork W2160941210 @default.
• W2040299750 hasRelatedWork W2345941387 @default.

• next